Company intelligence / Profile preview
Akebia Therapeutics
- Ownership
- Public · AKBA
- Employees
- ~150
- Development stage
- Commercial
Overview
Akebia has two FDA-approved products for CKD-related conditions. Vafseo® (vadadustat) was recently approved by the FDA for treating anemia due to CKD in patients on dialysis after an initial rejection. The company also markets Auryxia® (ferric citrate) for hyperphosphatemia and iron deficiency anemia. Akebia plans a Phase 3 trial to expand vadadustat’s label into non-dialysis CKD populations—a large potential market. Additional pipeline assets target acute kidney injury and retinopathy of prematurity
- Therapeutic areas
- OphthalmologyHematologyPulmonologyNephrology
- Modalities
- Small molecules (notably hypoxia-inducible factor prolyl hydroxylase inhibitors)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $117.9M
- Total revenue
- $236.2M
- Enterprise value
- $19.1M
Beyond the preview
Go deeper on Akebia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akebia Therapeutics.